ScienceDaily (Oct. 26, 2011) — A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive.
This research is being presented Oct. 23-27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.
Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.
For the full article please go here.
Welcome to the AIHCP blog. Members, vistors and friends are welcome to post on our blog. We believe that knowledge and opinion should be shared. We are professional health care organization offering continuing education and certification programs in a wide array of health care speciality practices, including: Grief Counseling, Legal Nurse Consulting, Case Management, Stress Management, Holistic & Integrative Health Care & more. Join the Discussion!
No comments:
Post a Comment